Disruptions to the hearing health sector

Isabelle Boisvert; Adam G. Dunn; Erik Lundmark; Jennifer Smith-Merry; Wendy Lipworth; Amber Willink; Sarah E. Hughes; Michele Nealon; Melanie Calvert

doi:10.1038/s41591-022-02086-6

Disruptions to the hearing health sector

Isabelle Boisvert, Adam G. Dunn, Erik Lundmark, Jennifer Smith-Merry, Wendy Lipworth, Amber Willink, Sarah E. Hughes, Michele Nealon, Melanie Calvert

Bloomberg School of Public Health

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	19-21
Number of pages	3
Journal	Nature medicine
Volume	29
Issue number	1
DOIs	https://doi.org/10.1038/s41591-022-02086-6
State	Published - Jan 2023

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1038/s41591-022-02086-6

Cite this

@article{ee64b8a6a85e422480b7562c077ca2b6,

title = "Disruptions to the hearing health sector",

author = "Isabelle Boisvert and Dunn, {Adam G.} and Erik Lundmark and Jennifer Smith-Merry and Wendy Lipworth and Amber Willink and Hughes, {Sarah E.} and Michele Nealon and Melanie Calvert",

note = "Funding Information: I.B. is a collaborator on projects that receive funding from Cochlear, but maintains academic independence for all research initiatives. S.E.H. receives funding from the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UKRI, National Technical Institute for the Deaf (NTID) COVID-19 Relief Fund, UK SPINE and declares personal fees from Cochlear, Astra Zeneca, CIS Oncolog, and Aparito outside the submitted work. M.C. receives funding from the National Institute for Health and Care Research (NIHR), UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Applied Research Collaboration (ARC) West Midlands, the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work; and a family member owns shares in GSK. The other authors declare having no relevant competing interests. The views expressed in this article are those of the authors and not necessarily those of their employing institutions.",

year = "2023",

month = jan,

doi = "10.1038/s41591-022-02086-6",

language = "English (US)",

volume = "29",

pages = "19--21",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Disruptions to the hearing health sector

AU - Boisvert, Isabelle

AU - Dunn, Adam G.

AU - Lundmark, Erik

AU - Smith-Merry, Jennifer

AU - Lipworth, Wendy

AU - Willink, Amber

AU - Hughes, Sarah E.

AU - Nealon, Michele

AU - Calvert, Melanie

N1 - Funding Information: I.B. is a collaborator on projects that receive funding from Cochlear, but maintains academic independence for all research initiatives. S.E.H. receives funding from the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UKRI, National Technical Institute for the Deaf (NTID) COVID-19 Relief Fund, UK SPINE and declares personal fees from Cochlear, Astra Zeneca, CIS Oncolog, and Aparito outside the submitted work. M.C. receives funding from the National Institute for Health and Care Research (NIHR), UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Applied Research Collaboration (ARC) West Midlands, the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work; and a family member owns shares in GSK. The other authors declare having no relevant competing interests. The views expressed in this article are those of the authors and not necessarily those of their employing institutions.

PY - 2023/1

Y1 - 2023/1

UR - http://www.scopus.com/inward/record.url?scp=85145720123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145720123&partnerID=8YFLogxK

U2 - 10.1038/s41591-022-02086-6

DO - 10.1038/s41591-022-02086-6

M3 - Comment/debate

C2 - 36604541

AN - SCOPUS:85145720123

SN - 1078-8956

VL - 29

SP - 19

EP - 21

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

Disruptions to the hearing health sector

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this